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RESPONSE: A CASE FOR COLLABORATIVE CARE
Rachel Gonzales, Ph.D., and David C. Perlman, M.D.
Rachel Gonzales: My background is in look-
ing at ways to assess hepatitis C accurately
and in identifying outcomes that may have
been affected by the combination of hepa-
titis C and continuous drug use. For exam-
ple, we have begun to look at whether
methamphetamine may be a particularly
risky drug to abuse because of its associa-
tion with high-risk sexual practices.
For those of us who don’t have a med-
ical background, Dr. Sylvestre’s article (2007)
is an excellent clinical overview. From a
research perspective, the article points to
several areas where studies may contribute
to more effective clinical management
and outcomes.
David Perlman: I’m an infectious disease
physician and have done a lot of work in the
health service aspects of infections in drug
abusers—for example, we are currently 
studying how best to screen methadone 
participants for hepatitis A, B, and C and
then link them to vaccinations or appro-
priate care.
Dr. Sylvestre’s main point bears repeat-
ing: Despair is unwarranted. There is a lot
of hype about this disease, and people can
get very scared. However, as she points out,
a significant percentage of patients have
spontaneous remissions; treatment can be
highly effective; and even infections that do
not respond to treatment do not always
progress to advanced liver disease.
Gonzales:Ideally, substance abuse clinicians’
attention to hepatitis C should commence
at the time the patient first enters treatment.
You want to find out if the patient has hep-
atitis C so that you can provide appropriate
additional screening, education, referral,
and monitoring.
Perlman: As Dr. Sylvestre says, hepatitis C
screening should be standard for people at
risk—which includes most people entering
substance abuse treatment. The sooner you
find out a patient has hepatitis C infection,
the sooner you can begin managing it.
Alternatively, the sooner you know some-
one is not infected, the sooner you can rein-
force behaviors to keep them that way.
Gonzales: I agree absolutely. It’s terribly
important to include messages for drug users
who aren’t yet infected in our models for
preventing hepatitis C.
Perlman:Along with warning patients about
the risk of injections with nonsterile or reused
equipment, the messages might discuss
heightened risks that are associated with the
specific places and contexts in which peo-
ple inject drugs. For example, data indicate
that injecting drugs outdoors is generally
riskier than injecting drugs indoors and that
infection rates are especially high among
people who inject drugs in shooting gal-
leries. The reasons may have to do with the
sharing of paraphernalia or other behaviors
that occur in these settings. Whatever the
reasons, this is good information to share
with patients.
Gonzales:The issue of whether continuing
drug abuse affects the potential toxicities of
hepatitis medications or the progress of the
disease is obviously very significant for cli-
nicians. One key to answering this and many
other issues will be getting accurate assess-
ments of the time of onset of hepatitis C,
especially in long-term drug abusers. That
information will enable us to untangle all
these relationships—what’s due to the drugs,
the infectious disease, the medication, or
any of these together.
Perlman: The question of reinfection as a
potential consequence of drug abuse or risky
sexual practices comes up sometimes. Dr.
Sylvestre cites data showing that this has not
been an overwhelming problem in study
populations so far. Clearly, there is a poten-
tial for reinfection, but just as clearly and
more importantly, the fact that someone
may relapse is no reason not to give all the
care he or she needs. After all, we don’t deny
treatment to substance abusers with HIV
infection, even though reinfection is poss-
ible there, too.
Program collaboration, system 
integration
Gonzales: I would like to see research on
what substance abuse programs around the
United States are doing in the area of infec-
tious disease management and education,
to set a context for moving forward. In the
programs I have observed, addiction spe-
cialists have played a more limited role in
hepatitis C management and education than
is optimal.
Perlman: Dr. Sylvestre does well to point
out that patients may benefit from being
co-managed by an addiction specialist and
someone with expertise in hepatitis C. The
role of addiction specialists is crucial. They
are uniquely equipped to help patients reduce
or eliminate their alcohol intake. That is
enormously important, because we know
that the hepatitis C virus and alcohol are
synergistically toxic. Similarly, anyone who
screens patients and helps them avoid or get
treated for concomitant hepatitis A and B
does them a tremendous service. The vac-
cines for hepatitis A and B are very safe and
highly effective. Addiction professionals can
also monitor and provide support for the
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in patients with hepatitis C, either as co-
occurring problems or as complications of
treatment.
There are many situations in which sub-
stance abuse treatment providers’ input can
be decisive. For example, methadone-
maintained patients sometimes have symp-
toms that they perceive to be opiate with-
drawal, but are, in fact, interferon side effects,
or vice versa. When this happens, substance
abuse professionals and hepatitis caregivers
can together tease out whether the patient’s
methadone dosage or interferon dosage
should be adjusted.
Gonzales: Substance abuse treatment pro-
viders and physicians who treat hepatitis
need to practice collaboratively to treat this
population. The psychosocial interventions
and hepatitis medication regimens both
place great demands on patients. Providers
of both services can motivate patients to
stay engaged in each other’s, as well as their
own, treatment programs. 
Perlman: Dr. Sylvestre says it is difficult to
find people to provide hepatitis care for drug
abusers, but that has not been my experi-
ence. Many caregivers and resources are
available and waiting for patients to show
up. The problem lies in the lack of inte-
gration between substance abuse and hep-
atitis treatment systems. We need to find
ways to motivate substance abusers to get
screened, to consider biopsy and treatment,
and to become engaged and keep appoint-
ments. As things stand, the vast majority
who receive referrals for possible hepatitis
treatment never follow through.
Gonzales: Learning how to integrate bet-
ter models of hepatitis C screening and refer-
ral into substance abuse treatment programs
is the subject of some of my research. One
project in the works is to begin to examine
some of the access barriers and service gaps
that affect treatment coordination. 
Perlman: We, too, are looking at ways to
try to enhance these outcomes. It is clear
that standard referral and education do not
engage or keep drug abusers in hepatitis
C care for terribly long. We are testing a
model that mixes case management with
some brief motivational interviewing. I
think it has the potential to be useful for
drug abusers with hepatitis C, but we won’t
know if it works until we finish our study.
Gonzales: Motivational interviewing is an
important part of the followup as well. We’re
going to be investigating its use at discharge
to foster the coordination of aftercare 
services.
Perlman: I endorse Dr. Sylvestre’s encour-
agement of substance abuse clinicians not
to be nihilistic about approaching drug
abusers to be screened and to consider treat-
ment for hepatitis C. On one point, though,
I think she overstates what the data show.
That’s when she interprets one study as sug-
gesting that hepatitis C may follow a more
benign course in drug abusers than in
nonabusers. Overall, I don’t believe there
are convincing comparative data to show
that the disease’s natural history and response
to treatment are truly better among drug
abusers than among nonabusers. That said,
these patients don’t need to do any better
than others to merit the same fair treatment
that any patient should get.
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